Trevena Inc. (TRVN) Company Value to Net Income
Trevena, Inc. (TRVN) has established a secure delivery system for specialized medications that minimizes supply chain disruptions to clinics. The price action history demonstrates the current -0.10 metric. Trevena, Inc. (TRVN) develops pain management therapies through selective receptor targeting to eliminate addiction. The business relies on an autonomous production cycle, rendering it resilient to global crises and transforming it into a reliable defensive asset.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_TRVN_-_Trevena-Inc._-_PE-Multiple "TRVN: trevena.com Market Cap to Earnings 07/04/2022 - 10/12/2024 | 👁️GURU.Markets👁️")
Analytical breakdowns for Trevena, Inc.
- share price and consensus valuation forecast:
- market capitalization details:
- balance sheet net asset value indicators:
- debt and solvency information:
Debt to Capital Trevena, Inc.|TRVN - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Trevena Inc|TRVN - Company Aggregate Debts|Debts to Book Capitalization Trevena, Inc.|TRVN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Trevena|Interim Coverage Ratio trevena.com
- business earnings and investment ratios data:
TRVN - Company Net Income|Net Profit Forecast Trevena, Inc.|TRVN - P/E Multiple|Projected Price to Earnings Trevena Inc.|TRVN - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevena, Inc.|TRVN - Operating profit before deduction of amortization|Earnings per share for the last four quarters Trevena|TRVN - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months trevena.com|TRVN - Net earnings per share growth this year|Net earnings per share growth forecast for next year Trevena, Inc.
Summary company analysis:TRVN, trevena.com
The ratio is calculated as market capitalization divided by the company's net income. This metric determines the investment payback period, reflecting the extent of the premium paid for the asset. For Trevena, Inc. (TRVN), costs associated with production greening and closed-loop water consumption are temporarily impacting bottom-line earnings. By analyzing the P/E based on company reports, an investor assesses business maturity. The price action of the line helps distinguish fundamental growth from speculative hype.
Competing companies
BIIB (biogen.com) - Market Price to Net Income Ratio|Price to Earnings Ratio Neurocrine Biosciences, Inc. (NBIX)|RGC (Regencell Bioscience Ltd) - Company Value to Net Income|P/E Multiple AXSM (Axsome Therapeutics Inc)|ACADIA Corp (ACAD) - Market Cap to Earnings|XENE: Price to Earnings Ratio|VKTX: Price to Earnings Ratio|SUPN: P/E Multiple|Market Cap to Earnings Catalyst Pharma (CPRX)|Price to Earnings Ratio Denali Therapeutics Inc|Price to Earnings Multiple HRMY (Harmony Corp)|P/E Multiple BHVN|P/E Multiple amylyx.com (AMLX)|Trevi Therapeutics, Inc. - Price to Earnings Ratio|Company Value to Net Income PRAX|Anavex Corp - P/E Multiple|Business Payback Period CeriBell EEG CBLL|prothena.com (PRTA) - Price to Earnings Ratio|Price to Earnings Multiple ALEC|ANNX (Annexon) - P/E Multiple|Price to Earnings Ratio Omeros Corp. (OMER)|Price to Earnings Ratio NGNE (Neurogene Corp)|Business Payback Period AC Immune Inc|Voyager Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio NMRA (neumoratx.com)|SCLX - Price to Earnings Ratio|Company Value to Net Income TVGN (Tevogen Bio Holdings Inc.)|ACOG (alphacognition.com) - Price to Earnings Ratio|CGTX (Cognition Therapeutics Inc.) - Price to Earnings Ratio|Price to Earnings Ratio Inhibikase Therapeutics|Price to Earnings Multiple SAVA (cassavasciences.com)|Price to Earnings Ratio Assertio Holdings, Inc. (ASRT)|coyatherapeutics.com - Price to Earnings Multiple|P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Market Cap to Earnings|ABOS: Price to Earnings Ratio|CRVO - P/E Multiple|alteritytherapeutics.com (ATHE) - Price to Earnings Ratio|Clene - Company Value to Net Income|Price to Earnings Ratio PepGen Inc|Market Cap to Earnings Jupiter Neurosciences, Inc. JUNS|Price to Earnings Ratio RLMD (Relmada Therapeutics)|Market Price to Net Income Ratio ANVS|Price to Earnings Ratio Grace Therapeutics GRCE|Company Value to Net Income AIFF|ANEW Medical, Inc. - P/E Multiple|Market Cap to Earnings NeuroSense Therapeutics|RVPH (Reviva Pharmaceuticals) - Price to Earnings Ratio|MTVA (MetaVia) - Price to Earnings Ratio|NRXS (NeurAxis) - P/E Multiple|Market Cap to Earnings Helius Medical Technologies Inc. HSDT|Price to Earnings Ratio Passage Bio, Inc. (PASG)|bionomics.com.au - Price to Earnings Multiple|P/E Multiple NERV (Minerva Neurosciences)|P/E Multiple athira.com ATHA|ADXN: Price to Earnings Ratio|Company Value to Net Income ALZN (Alzamend Neuro, Inc.)|CYCN: P/E Multiple|PTIX - Business Payback Period|Price to Earnings Ratio Pasithea Therapeutics Corp|Price to Earnings Multiple CRGT (Cortigent Medical)|P/E Multiple ATXI|Price to Earnings Ratio Brainstorm Cell Therapeutics Inc. BCLI|Cara Therapeutics, Inc - Price to Earnings Ratio|Business Payback Period Chromocell (CHRO)|ELYM: Price to Earnings Ratio|Intra-Cellular Therapies - Market Price to Net Income Ratio|Longboard Pharmaceuticals, Inc. (LBPH) - Price to Earnings Ratio|Marinus Pharmaceuticals Inc - Company Value to Net Income|Price to Earnings Ratio NKGN|Price to Earnings Ratio NRBO|Price to Earnings Ratio Sage Therapeutics, Inc. (SAGE)|synaptogen.com - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|WENA: Price to Earnings Multiple|Cerevel - P/E Multiple
